Press release
Anaplastic Thyroid Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Anaplastic Thyroid Cancer Pipeline
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
• DelveInsight's Anaplastic Thyroid Cancer pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
• The leading companies working in the Anaplastic Thyroid Cancer market include Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics Inc., Merck & Co, Iovance Biotherapeutics Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
• Promising Anaplastic Thyroid Cancer Pipeline Therapies in the various stages of development include HLX208, Lenvatinib, Nivolumab, Trametinib, Paclitaxel, Tremelimumab, MLN0128, AIC100 CAR T Cells, Efatutazone, PDR001, Avutometinib, Defactinib, and others.
• January 2024:- Dana-Farber Cancer Institute- A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer. This research study is a phase I/II study of MLN0128 in metastatic anaplastic thyroid cancer(ATC) and incurably poorly differentiated or radioidodine refractory differentiated thyroid cancer (DTC).
Request a sample and discover the recent advances in Anaplastic Thyroid Cancer Treatment Drugs @ Anaplastic Thyroid Cancer Pipeline Report- https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Anaplastic Thyroid Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anaplastic Thyroid Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anaplastic Thyroid Cancer clinical trial landscape.
Anaplastic Thyroid Cancer Overview
Anaplastic thyroid cancer, or ATC, is a type of thyroid cancer. The thyroid is a gland located in the front of your neck, just below the Adam's apple. It is responsible for sending the hormones to the rest of the body.
Find out more about Anaplastic Thyroid Cancer Treatment Drugs @ Drugs for Anaplastic Thyroid Cancer Treatment- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Anaplastic Thyroid Cancer Emerging Drugs Profile
• Sapanisertib: Takeda
• HLX208: Shanghai Henlius Biotech
Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment
The Anaplastic Large Cell Lymphoma pipeline report proffers an integral view of the Anaplastic Large Cell Lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Anaplastic Thyroid Cancer Pipeline Therapies @ Anaplastic Thyroid Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Anaplastic Thyroid Cancer Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics Inc., Merck & Co, Iovance Biotherapeutics Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
• Anaplastic Thyroid Cancer Pipeline Therapies- HLX208, Lenvatinib, Nivolumab, Trametinib, Paclitaxel, Tremelimumab, MLN0128, AIC100 CAR T Cells, Efatutazone, PDR001, Avutometinib, Defactinib, and others.
Dive deep into rich insights for new drugs for Anaplastic Thyroid Cancer Treatment, Visit @ Anaplastic Thyroid Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Anaplastic Thyroid Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Anaplastic Thyroid Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Sapanisertib: Takeda
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AIC100: AffyImmune Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Anaplastic Thyroid Cancer Key Companies
21. Anaplastic Thyroid Cancer Key Products
22. Anaplastic Thyroid Cancer- Unmet Needs
23. Anaplastic Thyroid Cancer- Market Drivers and Barriers
24. Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
25. Anaplastic Thyroid Cancer Analyst Views
26. Anaplastic Thyroid Cancer Key Companies
27. Appendix
For further information on the Anaplastic Thyroid Cancer Pipeline therapeutics, reach out to Anaplastic Thyroid Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Thyroid Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3489510 • Views: …
More Releases from DelveInsight Business Research LLP
ER+/ HER2-VE Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and …
DelveInsight's, "ER+/ HER2-VE Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the ER+/ HER2-VE Breast…
HER2-Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical an …
DelveInsight's, "HER2-Negative Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report
• DelveInsight's…
Metastatic Colorectal Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical a …
DelveInsight's, "Metastatic Colorectal Cancer Pipeline Insight 2024" report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from Metastatic Colorectal Cancer Pipeline Report
• DelveInsight's Metastatic…
Non Muscle Invasive Bladder Cancer Pipeline, FDA Approvals, Unmet Needs, Preclin …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Non…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Oligoastrocytoma Therapeutics Pipeline Review 2018
Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. The disease can be treated by surgical methods…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
